Please email the editors at 'theniche at nature.com' to propose new posts.

« October 2008 | Main | December 2008 »

Archive by date: November 2008

Bookmark in Connotea

ES cells change chromosomes; stem-cell CEO changes jobs

Two papers show how ES cells change in culture, and the head of NovoCell heads to a nonprofit.

First, the gossip, actually a news article from the San Diego Union Tribune. The head of Novocell, Alan Lewis, has headed over to the deep-pocketed non-profit Juvenile Diabetes Research Foundation, which has become a leading force in stem cell research. ( Bob Klein, head of CIRM, is on its board of directors, and the agency, along with NIH and CIRM, are American members of the International Stem Cell Initiative.) Alan Lewis is featured in our article on stem-cell start up companies, In search of a viable business model.

Next, one more thing for those culturing stem cells to worry about.

A paper in PNAS shows that mouse ES cells pick up copy number variants after just a few passages in routine culture. Here is a link to the research highlight. (We reported on CNVs in human ES cells several months ago and also ran a commentary about how to assess a stem cell genome).

More recently, two Nature Biotech papers show amplifications of sections of chromosomes containing several genes. Here’s the draft of that, as reported by excellent freelancer Simone Alves.

Continue reading "ES cells change chromosomes; stem-cell CEO changes jobs" »

Bookmark in Connotea

Thomson stem-cell companies consolidate

Three University of Wisconsin companies founded by ES-cell rock star James Thomson are joining up, according to an article from the Associated Press. The new company will be called CDI and combines Cellular Dynamics, Stem Cell Products and iPS Cells.

The first quote from the CEO is both vague and ambitious. Bob Peley’s company "intends to be the world leader in the industrialization of basic stem cell technology." Later, the article reveals the more-tangible goal of creating cardiomyocytes for drug screening. In fact, Cellular Dynamics had announced a deal with Roche to do this in the first quarter of this year. (See our article on this and other stem cell start-ups in http://www.nature.com/stemcells/2008/0810/081030/full/stemcells.2008.138.html In search of a viable business model )

Bookmark in Connotea

Stem-cell seeded trachea transplant

A patient who had severe tuberculosis is breathing much better after receiving a transplant of a trachea seeded with her own stem cells. The work, published in the Lancet, has been reported by the New York Times. A team of researchers from four European universities took a trachea from a decesased donor, removed its cells, leaving behind the extracellular structure, and re-seeded it with mesenchymal stem cells, a cell type found in bone marrow and elsewhere that can make (among many other things) cartilage.

Tony Atala at Wake Forset University has also made organs, in this case bladders, from patients' own cells. These have been studied in a handful of human patients. here's a CBS story that covers this and a profile from Nature Biotechnology.

Techniques to seed scaffolds with cells are growing apace; so are collaborations among disparate types of scientists. (See Thinking in three dimensions) In the case of the trachea, the trick was not to create a new scaffold but to decellularize and existing one. Work along the same lines has been caried out by Doris Taylor of Minnesota. (See Ghost heart has a tiny beat.)

Bookmark in Connotea

Stem-cell companies anticipate friendlier federal environment

News reports today say stem-cell companies are getting a boost from expectations that federal support for embryonic stem cell research will soon be less restricted, even if the companies don't work in embryonic stem cells. Crain's Detroit Business quotes officials of Oncomed, Aastrom, and more. The Bay Area newspaper also has a thoughtful piece.

StemCells Inc. has just announced a $20 million equity financing from an un-named institutional investor, through a shelf registration. The company has a Battens disease trial using neural stem cells derived from fetuses.

One of the menstrual stem-cell companies just announced a deal with the NIH. According to the press release, iron nanoparticles will be used to follow the human cells as they circulate around a mouse engineered to have breast cancer. (Actually, the press release only says "breast cancer model"; I''m guessing it's a mouse, though it could be a dog or a worm.) The ability to track cells is important, and so is figuring out how mesenchymal stem cells track to different organs. In fact, they may even help breast cancer metastasize. (See The dark side of mesenchymal stem cells.) Mesenchymal stem cells seem to come from many sources, and menstrual blood seems like one of them. (CryoCell is one of several companies that charges customers to bank cells for applications that have not yet been developed and may never be. See Stem cell banking: life line or sub-prime? For more on mesenchymal stem cells in general, see Questioning the self cell. For more on menstrual stem cells see Mesenchymal stem cells in the womb ).

Continue reading "Stem-cell companies anticipate friendlier federal environment" »

Bookmark in Connotea

Pfizer launches regenerative medicine unit

The pharmaceutical giant made it official today. It has launched a regenerative medicine unit co-located in Cambridge, UK and Cambridge, MA. It will have about 70 full-time employees, but the cheery news for stem-cell start-ups is the focus on deal-making. The company’s press release hinted that several scientific collaborations would be announced this week, and Pfizer’s head of bio-innovation reportedly said that this initiative might very well help some young companies stay alive through the financial crisis. (See the Wall Street Journal blog. For a broader view, see In search of a viable business model.)

The first time I heard a Pfizer official talk about this was at a stem cell conference in September (See Companies have company at stem-cell conference). The company line was caution: stem cells would be tools to finding, vetting, and assessing small molecule drugs. Cell therapies were a stretch. Sure, at that point, Pfizer had already invested in a little cell therapy company for eye disease, but those funds comprised the tiniest fraction of a giant R&D budget (See Pfizer dips a toe in stem-cell research). Today, ten days after the election of a stem-cell-friendly US president Pfizer sounds more ambitious. “Scientists at Pfizer Regenerative Medicine will explore the use of stem cells to develop future treatments that may prevent disability, repair failing organs and treat degenerative diseases. The ultimate goal will be to deliver new medicinal products that can pave the way for the use of cells as therapeutics.”

Bookmark in Connotea

Stem-cell transplant seems to fend off HIV

A bone marrow transplant seems to have suppressed HIV virus levels in blood. These results have been observed in a single patient and have not yet been reported in the peer-reviewed literature. According to news reports, a man infected with the AIDS virus received a bone marrow transplant as part of leukemia treatment. The donor of the bone marrow was naturally resistant to HIV infection because of a mutation in the CCR5 protein that the virus uses to gain entry into the cells it infects. Afterwards, the patient stopped taking his AIDS drugs. Twenty months later, though they cannot conclude that the virus has been vanquished, doctors cannot find evidence of leukemia or HIV in the 42-year-old patient.

See the reports in Reuters (shorter) and the Wall Street Journal online (more detailed.)

Continue reading "Stem-cell transplant seems to fend off HIV" »

Bookmark in Connotea

Obama likely to reverse federal funding ban on human embryonic stem cell research quickly

On Sunday, members of Obama's transition team said President-elect Barack Obama would review executive orders issued during the Bush Administration, and likely reverse many of them quickly after inauguration. Human embryonic stem cells was high on the list of likelies. This isn't a surprise, but the swiftness suggests that it is a priority, and also something that Obama must consider a relatively easy step.

Here's what the New York Times had to say. The stem cell research bit is described more fully on page 2, but no surprises.

Bookmark in Connotea

Research round-up: self-oranizing ES cells; more reprogrammig molecules

Lots of papers out recently. These will appear as separate articles on Thursday on the home page. Here are the titles ow. The articles are below.

Human cortical neural cell balls: Cells cultured in embryoid bodies self-organize into specific neural subtypes

Exogenous aids to reprogramming and self-renewal: Small molecules replace pluripotency gene and Wnt boosts self-renewal and reprogramming

Embryoid bodies get organized: Wnt signalling stimulates the beginnings of gastrulation

Continue reading "Research round-up: self-oranizing ES cells; more reprogrammig molecules" »

Bookmark in Connotea

Stem cell research wins in US election

In a historic US election, human embryonic stem cell research is coming out ahead.

In Michigan, scientists will now be able to derive new human embryonic stem cell lines from embryos donated by couples getting fertility treatments. See article in the Michigan Free Press.

A Colorado measure that would define a fertilized egg as a human being was also defeated. See the Los Angeles Times.

President-elect Barack Obama has also pledged to restore federal funding for human embryonic stem cell research.

Bookmark in Connotea

Double-locking against gene expression in embryonic stem cells

Here’s a research highlight that will appear soon on Nature Reports Stem Cells. This version has the addition of outside comment. It came in too late to be incorporated into the highlight, but I'm putting it here because I think it's interesting.
Multitasking methyltransferase: G9a silences gene expression two ways
As embryonic stem cells differentiate, the pluripotency gene known as Oct4 goes on lockdown. In fact, the guards to gene expression are doublelocked:the gene-encoding DNA strands are wound up into a structure called heterochromatin, in which the DNA is complexed with histones and other proteins in such a way that it is inaccessible to the transcriptional machinery. Furthermore, gene-expression machinery is kept at bay by chemical modifications to the DNA that signals the start of a gene. New work published in Nature Structural and Molecular Biology1 shows not only that both of these modifications are regulated by a single master protein, the histone methyltransferase G9a, but that this enzyme apparently brings about the inactivation of many early embryonic genes.
Led by Howard Cedar and Yehudit Bergman of Hadassah Hebrew University in Jerusalem, Israel, a team of researchers examined mouse embryonic stem (ES) cells as they began to differentiate. They used microarrays to compare cells at different stages of differentiation as well as cells that could and could not express G9a. This identified a number of genes besides Oct4 that were newly methylated during differentiation; in other words, as cells lost pluripotency, a set of genes was silenced by way of chemical modification to certain regions of DNA, and this methylation also seems to be under the control of G9a.
G9a helps convert chromatin into heterochromatin, in which gene expression is blocked.\Interestingly, DNA methylation and heterochromatinization seem to be independent of each other. The researchers blocked the heterochromatinization activity of G9a by introducing a mutation into the protein that prevents it from methylating a lysine 9 residue on histone protein H3 . This mutation did not, however, change patterns of gene methylation.
G9a seems to regulate DNA methylation by recruiting two well known DNA methyltransferases (Dnmt3a and Dnmt3b) to relevant sites in the genome, sites where G9a is helping to create heterochromatin. The authors speculate that other histone methyltransferases may also promote DNA methylation as well as heterochromatinization.
G9a directs both processes as mouse embryos transition between pre- and post-implantation stages. For a cell to be reprogrammed back to a pluripotent state, these states must be reversed, and while heterochromatin can be remodelled during cell division, DNA methylation patterns are often faithfully reproduced, and this, the authors believe, constitutes the main barrier to reprogramming. "G9a seems to serve as a master regulator involved in turning off pluripotency," says Cedar. His future work will be aimed at understanding how these processes reverse themselves when somatic cell genomes are reprogrammed to pluripotency.
1. Epsztejn-Litman, S. et al. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nature Struct. Mol. Biol., advance online publication, doi:10.1038/msmb.1476 (26 October 2008). | Article |

When I write research highlights, I try to find other scientists to put that work in perspective. For the highlight below, I contacted the corresponding author of an earlier paper on the role of microRNAs and methylation in embryonic stem cells, which seemed to suggest another mechanism for silencing Oct4 as ES cells differentiate. I received a reply too late to work it into the highlight, so I am putting the responses to my four questions below. This is a joint response from Lasse Sinkkonen in Friedrich Miescher Institute for Biomedical Research in Basel and Petr Svoboda from Institute of Molecular Genetics in Prague.

1) How does this finding from Cedar and Bergman fit in with your work, particularly in terms of the methylation of Oct4?

Our work was actually inspired by their work because we saw these data
at Bergman's talk while ago and we decided to test if Dicer-/-ES cells
behave like G9a and DNMT3a/b-/-. Their work is in no contradiction to
our work as we show that miRNAs regulate DNMT3a/b, which are required
for G9a-induced methylation. We only saw a small effect of miRNAs on G9a mRNA levels (~1.5-fold) and since H3K9methylation of Oct-3 promoter
occurs without problems, we believe that miRNAs mainly affect
methylation downstream of G9a and independently of its DNMT3 binding.

2) How surprising/important is this most recent finding?

It is very interesting because it was known for a long time that there is a connection between histone modifications and DNA methylation. G9a work is important because it provides a mechanistical link between histone methylation and DNA methylation by dual function histone
methyltransferase. And it is surprising to see that if the histone
methylation activity of G9a is abolished, G9a can still repress its
target gene via DNA methylation.

3) What additional studies should be done before the paper's conclusions can be accepted?

There are three studies from October (two in EMBO J), which corroborate
the model, so I don't have any major problem with accepting NCB
conclusions.

4) What new questions/ applications does this finding open up?

DNA methylation has been perceived by many as a security lock on
transcriptionally silenced genes, which appears after histone
modifications. The latest results raise a question whether DNA
methylation could have a more active role in gene silencing and could be more of a parallel silencing system than a follow up guardian.

Bookmark in Connotea

$1.4 billion stem-cell deal; stem-cell measure in Michigan; cloning resurrection; heart scaffolds


Besides electing a new president, voters in Michigan are standing in line this morning to decide on whether state scientists can try to derive embryonic stem cells from embryos left over after fertility treatments. (See Nature news coverage ). There are plenty of non-election stem cell stories out there, too.


Big stem-cell therapy deal
In a stock-boosting deal, Osiris has teamed up with established company Genzyme, to develop and commercialize two stem-cell products. Osiris gets $130 million by July 2009, and up to another $1.25 billion in other payments if and when the two products, Prochymal (for graft-vs-host disease and other indications) and Chondrogen (for osteoarthritis), start making serious money. Neither has yet been approved by the FDA. The products come from preparations of mesenchymal stem cells taken from healthy volunteers. (We've covered Osiris several times. See Stem cells for the heart, a new wave of clinical trials , Questioning the self cell, and In search of a viable business model)

Long-frozen mice cloned
Researchers in Kobe, Japan have derived mice from cells that had been frozen for sixteen years. Nuclei from long-dead brain and blood cells revived when placed into enucleated egg cells to generate embryos. In most animal cloning experiments, these embryos would be transferred to a surrogate mother; instead, the researchers first made embryonic stem cells from the embryos, then transferred nuclei from those living cells into enucleated eggs to make clones. Year-long frozen mice had been cloned before, and frozen tissue from a dead pet pit bull has also been used, but cells frozen for sixteen years are in much worse shape, and so naturally talk turns to woolly mammoths; the lead researcher, Teruhiko Wakayama, responsibly says that finding clonable cells in a mouse stored in a consistently cold freezer for a fraction of a century is considerably easier than accomplishing the same for cells going through varying levels of freezing for thousands of years. (Oh, yeah, and no one has made elephant embryonic stem cells or cloned a pachyderm, plus those animals are just a bit bigger with longer gestation times) (See the Great Beyond )

Stem-cell seeded scaffold beats
MIT scientists have made a biodegradable scaffold to grow heart muscle from stem cells, just published in Nature Methods and written up with a video in Technology Review. The idea is that the scaffold helps the cardiomyocytes ‘line up’ properly, then naturally degrades leaving only healthy tissue in its place. Right now, the patch is too thin to be of much use, but it’s a promising first step to repairing hearts in situ. Similar technologies have seeded stem cells into a naturally formed rat heart (See Ghost heart has a tiny beat ); there are lots of other approaches too. (See Christine Mummery: Regenerating the heart)